Final Approval In Glumetza Antitrust Deal Gives Attys $50M
A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million...To view the full article, register now.
Already a subscriber? Click here to view full article